You just read:

Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years

News provided by

Glenmark Pharmaceuticals

May 08, 2019, 08:00 ET